Telehealth claims

Your site may carry wording FDA has already quoted. See your strongest match, free.

FDA quoted 255 lines of telehealth marketing in 113 warning letters. In its own words: “The FDA is already implementing AI and other tech-enabled tools to proactively surveil and review drug ads.” FDA news release, 9 Sep 2025

A letter gives fifteen working days to reply. It can also reach the certification your Google and Meta ads depend on, and the processor that holds your revenue. What does one day of paused ads cost you?

Check my siteFree

Paste your site address. See whether your pages carry wording FDA quoted.

We email a link to confirm your address. Then our software reads your home page and up to 8 pages it links to, checks every sentence against the 255 lines, and shows your strongest match in under a minute. Public pages only. In the paid Letter Match a person reads every match and a licensed pharmacist signs the report.

FDA letter watchFree

When FDA posts new telehealth warning letters, we read your site the next morning and email you whether it carries wording of the kind newly quoted.

We email a link to confirm your address. So far FDA has posted three batches of telehealth warning letters: 9 Sep 2025, 20 Feb 2026 and 8 Jun 2026. We write only when FDA posts. Every email has an unsubscribe link.

As quoted by FDALetter batch
Sep 2025
“Same active ingredient as Ozempic and Wegovy”Implies a compounded drug is the approved one
Feb 2026
“Generic Zepbound, Mounjaro”A compounded drug is not a generic
Sep 2025
“Clinically proven ingredients”The trials were run on the approved product
Jun 2026
“FDA-approved pharmacy.”FDA grants no such status to a pharmacy
Sep 2025
“Tirzepatide (similar to Mounjaro)”Likens a compounded drug to the approved one
Lines quoted from FDA warning letters. Sellers not named.

The letters

113 letters in nine months. The same wording again and again.

FDA sent the letters in three batches. They cite the Food, Drug, and Cosmetic Act, sections 502(a) and 502(bb), which treat a compounded drug as misbranded if its labeling or its advertising is false or misleading in any particular.

113Telehealth warning letters in three batches: 58 on 9 Sep 2025, 30 on 20 Feb 2026 and 25 on 8 Jun 2026. Source: FDA warning-letter index.
32 of 87On 7 Oct 2026 we read the sites of 87 of the 113 letter recipients, and 32 still carried wording of the kind FDA quoted. Method: we ran Letter Match on every page we read and counted the sites with at least one strong match. Source: Claims Verified.
About 100Cease-and-desist letters FDA said it was issuing to companies with deceptive drug ads, alongside thousands of warnings. Source: FDA news release, 9 Sep 2025.
“Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not.”FDA telehealth warning letters, September 2025 batch, fda.gov warning letters

Price and scope

Check the letter wording now. Scope the full review when you need it.

One platform means one brand site with its treatment pages. More brands or a large ad library are scoped and priced before we start, so the number does not move after. The letters so far concern GLP-1 and erectile dysfunction drugs, so that is where Letter Match finds its matches.

Available now

FDA Letter Match

From $3,500 per platform

  • Letter Match reads every page of your site and checks each sentence against the wording FDA quoted in its 113 telehealth warning letters. Ads and emails you send us are checked the same way.
  • Each match comes with the FDA letter it echoes and wording that drops the claim. Where the problem is the product and not the sentence, the report says so.
  • A person reads every match before the report reaches you.
  • A licensed pharmacist signs the report.
  • Two business days.

A match means wording FDA has cited in letters to other firms. It is not a finding that your marketing breaks the law. A physician review of outcome and side-effect claims is available and is quoted with the scope.

Scoped on request

The full platform review

Priced per platform

  • Every page, ad, email, product photo and patient-facing flow ruled against the full telehealth standards, not only the letter wording.
  • Wording the standards allow for each finding that rewording can fix, and a signed Claims Review Report.
  • Covers weight loss, sexual health, hair loss, menopause and HRT, testosterone, fertility, skin and supplement add-ons.

Tell us what you publish and we reply with the scope, the price and the date we can deliver.

How it works

Every page read. Every match read by a person. One signed report.

FDA’s letters say the lines they cite are not an exhaustive list. So we read every page a visitor can open, and check each sentence against the wording FDA has quoted so far.

01 · Read

Every page

Your site, treatment pages and landing pages, as a visitor sees them. Nothing is sampled.

02 · Match

Against the wording FDA quoted

Each sentence is checked against the kinds of wording in the 255 lines FDA quoted, and paired with the closest letter. Tested on those 255 lines, the check recognises 88%. A person decides every match.

03 · Sign

A person, then a pharmacist

A person reads every match before the report is delivered. Each match comes with wording that drops the claim and the source it rests on. A licensed pharmacist signs the report.

One match

The wording FDA quoted most, and what replaces it.

“Same active ingredient as” a brand-name drug appears in more of the 113 letters than any other wording. Every match in your report is laid out like this.

Strong matchCompounded drug presented as the brand

Where: treatment page, first screen

As published

“Same active ingredient as Wegovy® and Ozempic®.”

Wording that drops the claim

“Compounded semaglutide, prescribed when a licensed clinician decides it is right for you. Compounded drugs are not FDA-approved.”

EchoesWording FDA has cited in letters to other telehealth firms, as false or misleading under FD&C Act 502(a) and 502(bb), 21 U.S.C. 352. Your report links each letter it echoes.

Scope

We review what you say. Your clinicians decide what you prescribe.

The review is external and read-only, and it is reported to you alone. Nothing we find is shared with FDA, a platform or a processor, unless the law requires it.

We review

  • Every page of your site, treatment pages included
  • Landing pages
  • Ads and emails you send us
  • Pages a visitor sees before a prescription

We do not review

  • Prescribing decisions or clinical protocols
  • Pharmacy operations or compounding quality
  • Health-data privacy, or ad tracking and pixels
  • Licensure or state telehealth law
  • Your LegitScript application
  • Text inside images and video (the full review covers product photos)

Before you ask

Four questions telehealth teams ask.

Does a match mean FDA has found a problem with our ads?

No. A match means your page uses wording FDA has cited in letters to other telehealth firms. Whether any line breaks the law is a question for your counsel. The report shows the FDA letter, your sentence and wording that drops the claim, so the decision is quick.

Does a clean report mean FDA cannot send us a letter?

No, and no outcome is guaranteed. A review can reduce risk. It cannot remove it. What it gives you is every page checked in advance, the allowed wording in hand, and a signed file that shows when you checked and what you changed.

We already have a letter. Can you help?

We can check every page and ad against the grounds in your letter and the wording FDA quoted to other firms, and document each change. Your counsel writes and sends the reply. We are not a law firm.

Is this legal or medical advice?

No. This is not legal advice or medical advice. It checks your wording against the wording in FDA’s published letters, with the source for every match. A person reads every match and a licensed pharmacist signs the report. Your counsel and your clinicians make the calls.

Request

Find the wording FDA has cited on your pages, and change it first.

Send us your site address. We reply with the scope and a fixed price before any work starts. Not legal advice. No outcome is guaranteed.